 management metastatic breast cancer Etoposide extensive use malignancies minor role treatment patients breast cancer Single-agent trials etoposide pretreated patients metastatic breast cancer low overall response rate patients evidence schedule dependence relationship dose intensity response sole single-agent trial untreated patients drug response rate untreated patients Combination therapy trials etoposide cyclophosphamide doxorubicin cisplatin demonstrated superiority drugs single agents cisplatin etoposide superior agent vitro studies hormone-sensitive breast cancer cells estradiol sensitivity etoposide-induced DNA cleavage future direction use etoposide breast cancer Currently use etoposide breast cancer investigational